Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer

Background: Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Vanessa Rouach, Inbal Goldshtein, Ido Wolf, Raphael Catane, Gabriel Chodick, Amit Iton, Naftali Stern, Daniel Cohen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2018-09-01
Edice:	Journal of Bone Oncology
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2212137418300496
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!